journal
Journals International Journal of Clini...

International Journal of Clinical Oncology

https://read.qxmd.com/read/38904888/risk-factors-affecting-delay-of-initiating-adjuvant-chemotherapy-for-stage-iii-colorectal-cancer
#1
JOURNAL ARTICLE
Shingo Maeda, Akira Ouchi, Koji Komori, Takashi Kinoshita, Yusuke Sato, Kei Muro, Hiroya Taniguchi, Toshiki Masuishi, Seiji Ito, Tetsuya Abe, Yasuhiro Shimizu
PURPOSE: Delay in initiating adjuvant chemotherapy (AC) after curative resection of colorectal cancer (CRC) has been reported to lead to poor prognosis, but few studies have looked at associated factors. This study aimed to identify risk factors for delay in initiating AC. METHODS: Data from 200 consecutive patients who underwent curative resection and AC for stage III CRC between 2013 and 2018 were retrospectively collected and analyzed. RESULTS: AC was initiated more than 8 weeks after surgery in 12...
June 21, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38904887/effectiveness-and-safety-of-primary-prophylaxis-with-g-csf-for-patients-with-ewing-sarcomas-a-systematic-review-for-the-clinical-practice-guidelines-for-the-use-of-g-csf-2022-of-the-japan-society-of-clinical-oncology
#2
JOURNAL ARTICLE
Takeshi Hirose, Mamoru Ito, Kenji Tsuchihashi, Yukinori Ozaki, Hiroshi Nishio, Eiki Ichihara, Yuji Miura, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Makoto Endo
BACKGROUND: Multidrug chemotherapy for Ewing sarcoma can lead to severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, "Does primary prophylaxis with G-CSF benefit chemotherapy for Ewing sarcoma?" and CQ #2, "Does G-CSF-based intensified chemotherapy improve Ewing sarcoma treatment outcomes?". METHODS: A comprehensive literature search was conducted in PubMed, Cochrane Library, and Ichushi web databases, including English and Japanese articles published from 1990 to 2019...
June 21, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38900215/effectiveness-and-safety-of-primary-prophylaxis-with-g-csf-during-chemotherapy-for-invasive-breast-cancer-a-systematic-review-and-meta-analysis-from-clinical-practice-guidelines-for-the-use-of-g-csf-2022
#3
JOURNAL ARTICLE
Kazuki Nozawa, Yukinori Ozaki, Tetsuhiro Yoshinami, Takamichi Yokoe, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano
INTRODUCTION: Chemotherapy for breast cancer can cause neutropenia, increasing the risk of febrile neutropenia (FN) and serious infections. The use of granulocyte colony-stimulating factors (G-CSF) as primary prophylaxis has been explored to mitigate these risks. To evaluate the efficacy and safety of primary G-CSF prophylaxis in patients with invasive breast cancer undergoing chemotherapy. METHODS: A systematic literature review was conducted according to the "Minds Handbook for Clinical Practice Guideline Development" using PubMed, Ichushi-Web, and the Cochrane Library databases...
June 20, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38896182/prognostic-impact-of-the-combination-of-p16-ink4a-p21-and-immunoscore-in-rectal-cancer
#4
JOURNAL ARTICLE
Toshihiro Nakao, Mitsuo Shimada, Kozo Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Yuma Wada, Toshiaki Yoshimoto
BACKGROUND: The association between p16INK4a and p21, a marker of cellular senescence, and the Immunoscore, an immunological prognostic indicator, in rectal cancer patients undergoing curative surgery were investigated. METHODS: A total of 82 patients who underwent curative surgery for rectal cancer were evaluated. The resected specimens were analyzed for p16INK4a , p21, CD3 and CD8 expression by immunohistochemistry. Immunoscore was calculated on the basis of CD3 and CD8 expressions...
June 19, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38896181/prognostic-significance-of-adjuvant-chemotherapy-in-stage-i-ii-endometrial-carcinoma-patients-who-underwent-lymphadenectomy
#5
JOURNAL ARTICLE
Jiro Suzuki, Hiroshi Tanabe, Hirofumi Michimae, Yuki Koike, Misato Kamii, Kazuaki Takahashi, Masataka Takenaka, Motoaki Saito, Hirokuni Takano, Kyosuke Yamada, Aikou Okamoto
BACKGROUND: Endometrial carcinoma, the most common gynecologic carcinoma, has an excellent prognosis post-surgery when diagnosed early. The role of postoperative adjuvant chemotherapy in stages I-II endometrial carcinoma remains controversial. This study assesses the efficacy of adjuvant chemotherapy in improving prognosis for these patients. METHODS: A retrospective analysis was conducted on 1223 stage I-II endometrial carcinoma patients who underwent surgical treatment including total hysterectomy, bilateral salpingo-oophorectomy, and lymph-node biopsy or dissection across four Jikei University School of Medicine-affiliated facilities between 2001 and 2018...
June 19, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38888683/difference-of-oncological-efficacy-between-two-immune-checkpoint-inhibitors-following-first-line-platinum-based-chemotherapy-in-patients-with-unresectable-metastatic-advanced-urothelial-carcinoma-a-multicenter-real-world-japanese-cohort
#6
JOURNAL ARTICLE
Makito Miyake, Nobutaka Nishimura, Yuki Oda, Tatsuki Miyamoto, Kota Iida, Kuniaki Inoue, Akira Tachibana, Takanosuke Yoshikawa, Keichi Sakamoto, Mikiko Ohnishi, Fumisato Maesaka, Norimi Takamatsu, Kosuke Mieda, Chihiro Ohmori, Toshihiko Matsubara, Mitsuru Tomizawa, Takuto Shimizu, Kenta Ohnishi, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Kazumasa Torimoto, Nobumichi Tanaka, Kiyohide Fujimoto
BACKGROUND: Maintenance avelumab is currently recommended for patients with unresectable and/or metastatic (mUC) achieving at least stable disease (SD) on first-line platinum-based chemotherapy (1L-CT). Pembrolizumab is an alternative therapeutic avenue for this patient cohort in clinical practice. We investigated real-world data, focusing on the correlation between response to 1L-CT and oncological efficacy of subsequent immune checkpoint inhibitor (ICI) therapy with avelumab or pembrolizumab...
June 18, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38884877/clinical-factors-predicting-the-outcome-of-salvage-radiotherapy-for-patients-with-biochemical-recurrence-after-radical-prostatectomy
#7
JOURNAL ARTICLE
Takeru Fujimoto, Takayuki Goto, Rihito Aizawa, Takashi Ogata, Kiyonao Nakamura, Takayuki Sumiyoshi, Yuki Kita, Kimihiko Masui, Takeshi Sano, Atsuro Sawada, Ryoichi Saito, Shusuke Akamatsu, Takashi Mizowaki, Takashi Kobayashi
BACKGROUND: It remains unclear which patients with biochemical recurrence after prostatectomy are most suitable for salvage radiotherapy. We evaluated the parameters related to outcomes. METHODS: We retrospectively evaluated patients who underwent salvage therapy for biochemical recurrence after prostatectomy between 2005 and 2019. This study aimed to evaluate biochemical recurrence-free survival (bRFS) after salvage radiotherapy and elucidate the parameters associated with bRFS...
June 17, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38865026/primary-prophylaxis-with-g-csf-for-patients-with-non-round-cell-soft-tissue-sarcomas-a-systematic-review-for-the-clinical-practice-guidelines-for-the-use-of-g-csf-2022-of-the-japan-society-of-clinical-oncology
#8
JOURNAL ARTICLE
Takeshi Hirose, Mamoru Ito, Kenji Tsuchihashi, Yukinori Ozaki, Hiroshi Nishio, Eiki Ichihara, Yuji Miura, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Makoto Endo
BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) is an essential supportive agent for chemotherapy-induced severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, "Does primary prophylaxis with G-CSF benefit chemotherapy for non-round cell soft tissue sarcoma (NRC-STS)?" and CQ #2, "Does G-CSF-based intensified chemotherapy improve NRC-STS treatment outcomes?" for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology...
June 12, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38865025/therapeutic-effect-of-dose-dense-paclitaxel-plus-carboplatin-with-or-without-bevacizumab-for-japanese-patients-with-epithelial-ovarian-cancer
#9
JOURNAL ARTICLE
Yuki Kochi, Satoshi Hosoya, Nozomu Yanaihara, Chie Nagata, Rie Honda, Miwako Shimazaki, Kota Yokosu, Takafumi Kuroda, Motoaki Saito, Hiroshi Tanabe, Kyosuke Yamada, Hirokuni Takano, Aikou Okamoto
BACKGROUND: Evidence regarding chemosensitivity to different therapeutic regimens in epithelial ovarian cancer (EOC) remains limited. This study aimed to investigate EOC implementation in daily clinical practice and reveal favorable regimens for EOC among Japanese patients. METHODS: We retrospectively collected clinical data of patients newly diagnosed with EOC from 2012 to 2021 at our affiliated institutions. We evaluated overall survival (OS) and progression-free survival (PFS) of conventional paclitaxel plus carboplatin (TC) vs...
June 12, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38858229/statistics-of-bone-sarcoma-in-japan-report-from-the-population-based-cancer-registry-in-japan
#10
JOURNAL ARTICLE
Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Eisuke Kobayashi, Ayumu Arakawa, Chitose Ogawa, Yoko Kato, Takahiro Higashi, Akira Kawai
BACKGROUND: No previous reports have characterized national bone sarcoma profiles overall. We examined the nationwide statistics for bone sarcoma in Japan using data from the National Cancer Registry (NCR), a population-based cancer registry. METHODS: We identified 3,755 patients with bone sarcomas entered in the NCR during 2016-2019 using International Classification of Diseases-Oncology, Third Edition codes for cancer topography and morphology. We extracted data on patient demographics, tumor details (reason for diagnosis, tumor location, histology, extent of disease), hospital volume/type, treatment, and prognosis for each patient...
June 11, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38856798/appropriate-definition-of-non-metastatic-castration-resistant-prostate-cancer-nmcrpc-and-optimal-timing-of-androgen-receptor-signaling-inhibitor-arsi
#11
JOURNAL ARTICLE
Kazuhiro Matsumoto, Takeo Kosaka, Toshikazu Takeda, Keishiro Fukumoto, Yota Yasumizu, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Hiroshi Asanuma, Mototsugu Oya
BACKGROUND: Defined by rising PSA levels under androgen deprivation therapy (ADT) despite no visible metastases on conventional imaging, non-metastatic castration-resistant prostate cancer (nmCRPC) represents a complex clinical challenge. A significant subset of these patients rapidly develops metastatic disease, negatively impacting survival. We examined the difference in prognosis of nmCRPC patients according to the timing of therapeutic interventions with androgen receptor signaling inhibitor (ARSI)...
June 10, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38853186/the-mir-199a-5p-hif1%C3%AE-dual-regulatory-axis-participates-in-hypoxia-induced-aggressive-phenotypes-of-oral-squamous-cell-carcinoma-oscc-cells
#12
JOURNAL ARTICLE
Xing Chen, Jianjun Yu, Hao Tian, Xu Cai
BACKGROUND: The late-stage diagnosis and distant metastasis of oral squamous cell carcinoma (OSCC) remain a huge challenge to clinical treatment for OSCC. During the past decades, targeting glycolysis-inducing factors becomes an attractive new strategy in OSCC therapies. METHODS: OSCC cells were stimulated with hypoxia or transfected with agomir-199a-5p, antagomir-199a-5p, and siRNA for HIF1A, cell proliferation was detected by CCK-8 assay; HIF1α, GLUT1, HK2 and LDHA expression levels were examined with western blot; miR-199 expression was determined with RT-PCR; cell migratory and invasive abilities were examined using wound healing and transwell assays; the lactate and glucose in culture medium were also determined...
June 9, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38850448/recent-developments-and-future-directions-of-first-line-systemic-therapy-combined-with-immunotherapy-for-advanced-or-metastatic-urothelial-carcinoma-a-historical-perspective-on-treatment-evolution
#13
REVIEW
Atsunari Kawashima, Yu Ishizuya, Yoshiyuki Yamamoto, Taigo Kato, Koji Hatano, Norio Nonomura
Urothelial carcinoma presents significant treatment challenges, especially in advanced stages. Traditionally managed with platinum-based chemotherapy, the advent of immunotherapies, particularly immune checkpoint inhibitors, has revolutionized urothelial carcinoma treatment. This review explores the evolution of urothelial carcinoma management, focusing on the transition from immune checkpoint inhibitors monotherapy to innovative combination therapies. Pembrolizumab, following the KEYNOTE-045 trial, emerged as a pivotal ICI in pretreated metastatic urothelial carcinoma, outperforming traditional chemotherapy...
June 8, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38844668/safety-of-nivolumab-monotherapy-in-five-cancer-types-pooled-analysis-of-post-marketing-surveillance-in-japan
#14
JOURNAL ARTICLE
Kenji Hiraizumi, Chikara Honda, Ayu Watanabe, Takafumi Nakao, Shuichi Midorikawa, Hiromi Abe, Nobuki Matsui, Tsunehisa Yamamoto, Takahiko Sakamoto
BACKGROUND: Nivolumab has been approved for treating ≥ 10 cancer types. However, there is limited information on the incidence of rare, but potentially serious, treatment-related adverse events (TRAEs), as well as notable TRAEs in patients with certain medical disorders or older patients in Japan. METHODS: We performed pooled analyses of data from published post-marketing surveillance in Japan of nivolumab monotherapy for patients with malignant melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancer, and gastric cancer to determine the frequencies of 20 categories of TRAEs of special interest overall and in patient groups with higher perceived safety risks (history of autoimmune disease, interstitial lung disease, tuberculosis, or hepatitis B/C; patients vaccinated during nivolumab treatment; and older patients [≥ 75 years])...
June 6, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38839664/an-evaluation-model-of-hepatic-steatosis-based-on-ct-value-and-serum-uric-acid-hdl-cholesterol-ratio-can-predict-intrahepatic-recurrence-of-colorectal-cancer-liver-metastasis
#15
JOURNAL ARTICLE
Yuan Li, E-Er-Man-Bie-Ke Jin-Si-Han, Cheng Feng, Weili Zhang, Hao Wang, Shaopu Lian, Jianhong Peng, Zhizhong Pan, Binkui Li, Yujing Fang, Zhenhai Lu
BACKGROUND: Intrahepatic recurrence is one of the main causes of treatment failure in patients with colorectal cancer liver metastasis (CRLM). Hepatic steatosis was reported to provide fertile soil for metastasis. The effect of irinotecan-inducted hepatic steatosis on the progression of liver metastasis remains to be verified. Therefore, we aim to clarify the effect of hepatic steatosis on postoperative intrahepatic recurrence in CRLM and whether it is relevant to irinotecan-based chemotherapy...
June 5, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38836937/pmda-regulatory-update-on-approval-and-revision-of-the-precautions-for-use-of-anticancer-drugs-approval-of-pembrolizumab-for-gastric-and-biliary-tract-cancer-and-encorafenib-and-binimetinib-for-thyroid-cancer-in-japan
#16
EDITORIAL
https://read.qxmd.com/read/38833114/final-analyses-of-the-prospective-controlled-trial-on-the-efficacy-of-uracil-and-tegafur-leucovorin-as-an-adjuvant-treatment-for-stage-ii-colon-cancer-with-risk-factors-for-recurrence-using-propensity-score-based-methods-jfmc46-1201
#17
JOURNAL ARTICLE
Yutaka Ogata, Sotaro Sadahiro, Kazuhiro Sakamoto, Takashi Tsuchiya, Takao Takahashi, Hiroki Ohge, Toshihiko Sato, Ken Kondo, Hideo Baba, Michio Itabashi, Masataka Ikeda, Madoka Hamada, Kiyoshi Maeda, Hiroyuki Masuko, Keiichi Takahashi, Mitsuo Kusano, Ichinosuke Hyodo, Junichi Sakamoto, Masataka Taguri, Satoshi Morita
BACKGROUND: The efficacy of adjuvant chemotherapy for high-risk stage II colon cancer (CC) has not been well established. Using propensity score matching, we previously reported that the 3-year disease-free survival (DFS) rate was significantly higher in patients treated with uracil and tegafur plus leucovorin (UFT/LV) against surgery alone. We report the final results, including updated 5-year overall survival (OS) rates and risk factor analysis outcomes. METHODS: In total, 1902 high-risk stage II CC patients with T4, perforation/penetration, poorly differentiated adenocarcinoma/mucinous carcinoma, and/or < 12 dissected lymph nodes were enrolled in this prospective, non-randomized controlled study based on their self-selected treatment...
June 4, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38833113/gustave-roussy-immune-score-as-a-prognostic-biomarker-in-patients-with-platinum-refractory-metastatic-urothelial-carcinoma-treated-with-pembrolizumab-yushima-study
#18
JOURNAL ARTICLE
Kenji Tanabe, Shuichiro Kobayashi, Yuya Maezawa, Kensaku Ishihara, Naoki Inoue, Keita Izumi, Motohiro Fujiwara, Masahiro Toide, Takanobu Yamamoto, Sho Uehara, Saori Araki, Masaharu Inoue, Ryoji Takazawa, Noboru Numao, Yukihiro Ohtsuka, Hajime Tanaka, Soichiro Yoshida, Yasuhisa Fujii
BACKGROUND: This study aimed to investigate the prognostic value of the Gustave Roussy Immune score (GRIm-score) in platinum-refractory metastatic urothelial carcinoma (UC) treated with pembrolizumab. METHODS: This multicenter retrospective study (YUSHIMA study) evaluated 331 patients with metastatic UC treated with pembrolizumab after platinum-based chemotherapy between January 2018 and June 2023 at 13 institutions. We collected pretreatment variables, including the GRIm-score based on serum albumin, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio...
June 4, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38831224/impact-of-cancer-cachexia-on-survival-in-patients-with-pancreatic-cancer-and-the-efficacy-of-first-line-chemotherapy
#19
LETTER
Tsutomu Nishida, Kana Hosokawa, Aya Sugimoto
No abstract text is available yet for this article.
June 3, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38829471/trends-in-the-surgical-treatment-for-metastatic-spinal-tumor-in-japanese-administrative-data-between-2012-and-2020
#20
JOURNAL ARTICLE
Kentaro Yamada, Toshitaka Yoshii, Mikayo Toba, Satoru Egawa, Shingo Morishita, Yu Matsukura, Takashi Hirai, Atsushi Kudo, Kiyohide Fushimi
BACKGROUND: Both cancer diagnosis/treatment modality and surgical technique for the spine have been developed recently. Nationwide trends in the surgical treatment for metastatic spinal tumors have not been reported in the last decades. This study aimed to examine recent trends in the surgical treatment for spinal metastasis and in-hospital patient outcomes using nationwide administrative hospital discharge data. METHODS: The Diagnosis Procedure Combination database from 2012 to 2020 was used to extract data from patients who underwent surgical procedures for spinal metastasis with the number of non-metastatic spinal surgery at the institutions that have performed metastatic spine surgeries at least one case in the same year...
June 3, 2024: International Journal of Clinical Oncology
journal
journal
32641
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.